Proton Therapy for Recurrent Glioma
Jeffrey J. Raizer, MD, provides an overview of a study that analyzed the overall survival and toxicity profile of proton therapy for large-volume re-irradiation for patients with recurrent glioma.
Clinical Pearls
Jeffrey J. Raizer, MD, Co-Director, Northwestern Brain Tumor Institute, Professor in Neurology, Ken and Ruth Davee Department, Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, provides an overview of a study that analyzed the overall survival and toxicity profile of proton therapy for large-volume re-irradiation for patients with recurrent glioma.
- The study looked at patients who failed bevacizumab or standard therapy. Proton therapy was used in addition to bevacizumab and temozolomide with the idea that re-irradiating the volume might result in less toxicity.
- Though the study only enrolled a small number of patients, this approach looks beneficial.
- Patients on the trial survived for 6-7 months, when the standard is typically 2-3 months. This approach elicited no additional toxicity.
<<<
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
